EuropaBio National Associations Council Summit 2022 (French Presidency): how does biotechnology deliver the Industrial strategy across sectors?
EuropaBio and members France Biotech, MabDesign and Bioeconomy for Change are delighted to invite delegates to the second National Associations Council Summit 2022, being hosted during the Council Presidency of France. ‘Biotechnology: Delivering Europe’s industrial strategy across sectors’ will take place on 3 March 2022, 10:00-13.30 CET online.
National Associations, biotech companies of all sizes, policy makers and others will discuss the commercial pathways for healthcare biotechnology to deliver innovative therapeutics to patients, and for industrial biotechnology to drive economic growth and market development.
’Europe is showing right now, how to be competitive as a result of innovative advances in Member states. We are a leader in Research and Development and Innovation, and this has to translate rapidly into contributions towards Europe’s industrial strategy. For the second year, our National Associations Council Summit invites members and stakeholders to address healthcare and industrial biotechnology priorities in the light of the Agenda of the French Presidency of the Council of the EU. European and national performance is intertwined, and the policies that drive biotechnology have to work across European countries’’, said Dr Claire Skentelbery, Director General of EuropaBio.
The Summit will be divided into two parts: Healthcare biotechnology: Innovative therapeutics to patients in Europe; and Industrial biotechnology and bioeconomy: Growth and innovation to market.
The Healthcare biotechnology panel addresses how we transform research to sustainable and accessible healthcare. Speakers and participants will discuss national and EU initiatives, and policies, that help move research advances through to patient uptake. Critically, how we create momentum and investment into technologies, skills and infrastructure for next generation therapies in Europe, and how Europe can enable cross-border healthcare delivering benefit for European citizens.
The second part of the Summit will be devoted to Industrial biotechnology and bioeconomy and its growth and innovation to market. The panel will discuss initiatives and policies that enable long term investment into largescale manufacture and ensuring a competitive next generation industrial landscape. Finally, the discussion will include novel foods and their role in Europe’s future sustainability and competitiveness, with the critical policy and regulatory framework that enables investment.